J Breast Cancer.  2007 Sep;10(3):211-216. 10.4048/jbc.2007.10.3.211.

The Clinical and Histopathological Characteristics of Male Breast Cancer Patien

• Cho J
• Han W
• Ko E
• Lee JW
• Jung SY
• Kim EK
• Lee HC
• Park IA
• Oh SK
• Youn YK
• Kim SW
• Hwang KT
• Noh DY

• KMID: 2175038
• DOI: http://doi.org/10.4048/jbc.2007.10.3.211

Abstract

PURPOSE: Breast cancer in male is uncommon, accounting for approximately 1% of all breast cancer and less than 1.5% of all the malignant neoplasms in males. The information concerned with the treatment of male breast cancer is limited. The objective of this study is to evaluate the histopathologic characteristics and clinical outcome of male breast cancer patients.
METHODS
We retrospectively analyzed the medical record of 17 male breast cancer patients who had been operated on Seoul National University Hospital between 1996 and 2006.
RESULTS
The peak age of incidence was the 6th decade and the mean age of the patients was 56.2 yr. The most common symptom was a palpable mass and the mean duration of symptoms was 13 months. Fifty-three percent of the patients were stage 0 or I. Mastectomy was performed in 15 cases and lumpectomy was performed in 2 cases. Twelve patients received adjuvant hormonal therapy. The median duration of follow up was 28 months. Of the two patients with distant relapse, one patient died due to multiple metastasis and the other patient is still alive. The other patients are still alive without any evidence of metastasis or recurrence.
CONCLUSION
Active diagnosis, appropriate treatments (surgery and adjuvant therapy) and close follow up are necessary for male patients who have a palpable mass in their breast.

Keyword

Male breast cancer

MeSH Terms

Breast
Breast Neoplasms
Breast Neoplasms, Male*
Diagnosis
Follow-Up Studies
Humans
Incidence
Male
Male*
Mastectomy
Mastectomy, Segmental
Medical Records
Neoplasm Metastasis
Recurrence
Retrospective Studies
Seoul

Reference

1. Korean Central Cancer Registry. 2002 Annual report of the Korean Central Cancer Registry. 2003. Gwacheon: Ministry of Health and Welfare.

2. Sasco AJ, Lowenfels AB, Pasker-de Jong J. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993. 53:538–549.

3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003. 53:5–26.

4. Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am. 1990. 70:1165–1177.

5. The Korean Breast Cancer Society. Survival analysis of Korean breast cancer patients diagnosied between 1993 and 2002-A nationwide study of the cancer registry. J Breast Cancer. 2006. 9:214–229.

6. Kidmas AT, Ugwu BT, Manasseh AN, IYA D, Opaluwa AS. Male breast malignancy in Jos University Teaching Hospital. West Afr J Med. 2005. 24:36–40.

7. Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985. 74:371–375.

8. Lee PC, Son BH, Kwon JN, Lee WB, Lee KM. Clinical feature of the male breast cancer-13 cases. J Korean Breast Cancer Soc. 2004. 7:193–198.

9. Back JM, Sung GY, Lee DS, Kim W, Pack IY, Jung SS, et al. Male breast cancer. J Breast Cancer. 2005. 8:123–127.

10. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997. 60:313–319.

11. Hultborn R, Hanson C, Kopf I, Verbiene I, Warnhammar E, Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res. 1997. 17:4293–4297.

12. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002. 31:55–59.

13. Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994-1998. Eur J Cancer Prev. 2002. 11:253–263.

14. Pollan M, Gustavsson P, Floderus B. Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. Am J Ind Med. 2001. 39:276–285.

15. Ron E, Ikeda T, Preston DL, Tokuaka S. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst. 2005. 97:603–605.

16. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, et al. Current management of male breast cancer: a review of 104 cases. Ann Surg. 1992. 215:451–459.

17. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006. 367:595–604.

18. Borgen PI, Senie RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997. 4:385–388.

19. Kraybill WG, Kaufman R, Kinne D. Treatment of advanced male breast cancer. Cancer. 1981. 47:2185–2189.

20. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002. 137:678–687.

21. Hultborn R, Friberg S, Hultborn KA, Peterson LE, Ragnhult I. Male breast carcinoma. II. A study of the total material reported to the Swedish Cancer Registry 1958-1967 with respect to treatment, prognostic factors and survival. Acta Oncol. 1987. 26:327–341.

22. Donegan WL, Redlich PN, Lang PJ, Gall MT. Cancer of the breast in males. A multiinstitutional survey. Cancer. 1998. 83:498–509.

23. The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2002. J Korean Breast Cancer Soc. 2004. 7:72–83.

24. The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using breast caner registration program. J Breast Cancer. 2006. 9:151–161.

25. Shin HJ, Han W, Kim SW, Hwang KT, Hwang SE, Lee JE, et al. Postoperative survival and prognostic factors in breast cancer: a single center analysis of 4,063 cases. J Breast Cancer. 2006. 9:55–60.